Jointown Pharmaceutical Group reports strong Q3 growth, expands business scope

Jointown Pharmaceutical Group reported a 5.41% increase in operating revenue to 38.22 billion yuan for Q3 2025, with net profit attributable to shareholders rising 8.46% to 530 million yuan. Year-to-date for the first nine months of 2025, operating revenue reached 119.33 billion yuan, up 5.20%, and net profit attributable to shareholders grew 16.46% to 1.98 billion yuan. These results were bolstered by growth in pharmaceutical distribution, branded agency, industrial pharmacy, and digital logistics, alongside the successful issuance of REITs for its pharmaceutical warehousing and logistics infrastructure, which added 438 million yuan to net profit.

The company's Articles of Association were revised to reflect an expanded business scope, now including loading and unloading, general cargo warehousing, catering, business training, conference and exhibition services, enterprise management, legal consulting, health consulting, and market and consulting planning services. This broadens Jointown's strategic market reach. The legal representative's role was clarified to specify that the chairman of the board of directors acts as the legal representative.

Furthermore, a new “Management System for Shares Held by Directors and Senior Management and Their Changes” was approved, ensuring compliance with regulations on shareholdings and transactions. This system formalizes disclosure requirements for share movements by directors and senior management, underscoring the company’s commitment to good governance.